全文获取类型
收费全文 | 2550篇 |
免费 | 216篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 62篇 |
妇产科学 | 35篇 |
基础医学 | 367篇 |
口腔科学 | 78篇 |
临床医学 | 223篇 |
内科学 | 663篇 |
皮肤病学 | 24篇 |
神经病学 | 249篇 |
特种医学 | 90篇 |
外国民族医学 | 5篇 |
外科学 | 328篇 |
综合类 | 38篇 |
一般理论 | 6篇 |
预防医学 | 266篇 |
眼科学 | 26篇 |
药学 | 163篇 |
中国医学 | 3篇 |
肿瘤学 | 137篇 |
出版年
2023年 | 25篇 |
2022年 | 32篇 |
2021年 | 54篇 |
2020年 | 31篇 |
2019年 | 37篇 |
2018年 | 62篇 |
2017年 | 44篇 |
2016年 | 44篇 |
2015年 | 42篇 |
2014年 | 72篇 |
2013年 | 116篇 |
2012年 | 149篇 |
2011年 | 157篇 |
2010年 | 87篇 |
2009年 | 65篇 |
2008年 | 142篇 |
2007年 | 146篇 |
2006年 | 140篇 |
2005年 | 114篇 |
2004年 | 109篇 |
2003年 | 93篇 |
2002年 | 107篇 |
2001年 | 64篇 |
2000年 | 65篇 |
1999年 | 50篇 |
1998年 | 38篇 |
1997年 | 23篇 |
1996年 | 21篇 |
1995年 | 31篇 |
1994年 | 23篇 |
1993年 | 25篇 |
1992年 | 62篇 |
1991年 | 54篇 |
1990年 | 56篇 |
1989年 | 40篇 |
1988年 | 41篇 |
1987年 | 33篇 |
1986年 | 17篇 |
1985年 | 21篇 |
1984年 | 15篇 |
1983年 | 19篇 |
1982年 | 16篇 |
1981年 | 13篇 |
1979年 | 20篇 |
1978年 | 15篇 |
1976年 | 11篇 |
1974年 | 14篇 |
1973年 | 13篇 |
1971年 | 11篇 |
1970年 | 12篇 |
排序方式: 共有2776条查询结果,搜索用时 31 毫秒
101.
102.
103.
104.
Hans Jürgen Netter Hans Herbert Guldner Carin Szostecki Heinz-Jürgen Lakomek Hans Will 《Arthritis \u0026amp; Rheumatology》1988,31(5):616-622
A human liver complementary DNA expression library was screened using sera from patients with high titers of autoantibodies, to search for clones expressing major autoantigens that are relevant in connective tissue diseases. One of the clones isolated expressed a major epitope(s) that was immunoreactive with anti-U1 RNP sera, as shown by several techniques. Affinity-purified autoantibodies from the cloned RNP protein specifically recognized the 68-kd U1 RNP protein of HeLa cell nuclear extracts. All sera containing anti-U1 RNP antibodies detected by immunodiffusion, counterimmuno-electrophoresis, or immunoblotting also recognized the cloned RNP protein. The RNP antigen-expressing bacterial colonies and the partially purified cloned RNP fusion protein have been applied to fast and sensitive immunologic assays for the detection and quantification of anti-U1 RNP antibodies. 相似文献
105.
Jon B. Toledo Matthias Arnold Gabi Kastenmüller Rui Chang Rebecca A. Baillie Xianlin Han Madhav Thambisetty Jessica D. Tenenbaum Karsten Suhre J. Will Thompson Lisa St. John-Williams Siamak MahmoudianDehkordi Daniel M. Rotroff John R. Jack Alison Motsinger-Reif Shannon L. Risacher Colette Blach Joseph E. Lucas Rima Kaddurah-Daouk 《Alzheimer's & dementia》2017,13(9):965-984
Introduction
The Alzheimer's Disease Research Summits of 2012 and 2015 incorporated experts from academia, industry, and nonprofit organizations to develop new research directions to transform our understanding of Alzheimer's disease (AD) and propel the development of critically needed therapies. In response to their recommendations, big data at multiple levels are being generated and integrated to study network failures in disease. We used metabolomics as a global biochemical approach to identify peripheral metabolic changes in AD patients and correlate them to cerebrospinal fluid pathology markers, imaging features, and cognitive performance.Methods
Fasting serum samples from the Alzheimer's Disease Neuroimaging Initiative (199 control, 356 mild cognitive impairment, and 175 AD participants) were analyzed using the AbsoluteIDQ-p180 kit. Performance was validated in blinded replicates, and values were medication adjusted.Results
Multivariable-adjusted analyses showed that sphingomyelins and ether-containing phosphatidylcholines were altered in preclinical biomarker-defined AD stages, whereas acylcarnitines and several amines, including the branched-chain amino acid valine and α-aminoadipic acid, changed in symptomatic stages. Several of the analytes showed consistent associations in the Rotterdam, Erasmus Rucphen Family, and Indiana Memory and Aging Studies. Partial correlation networks constructed for Aβ1–42, tau, imaging, and cognitive changes provided initial biochemical insights for disease-related processes. Coexpression networks interconnected key metabolic effectors of disease.Discussion
Metabolomics identified key disease-related metabolic changes and disease-progression-related changes. Defining metabolic changes during AD disease trajectory and its relationship to clinical phenotypes provides a powerful roadmap for drug and biomarker discovery. 相似文献106.
107.
Pearl P. Y. Lie Apple Y. N. Chan Dolores D. Mruk Will M. Lee C. Yan Cheng 《Proceedings of the National Academy of Sciences of the United States of America》2010,107(25):11411-11416
In epithelia, a primary damage of tight junctions (TJ) always leads to a secondary disruption of adherens junction (AJ), and vice versa. This response, if occurring in the testis, would disrupt spermatogenesis because the blood–testis barrier (BTB) must remain intact during the transit of spermatids in the seminiferous epithelium, which is associated with extensive apical ectoplasmic specialization (apical ES, a testis-specific AJ type) restructuring. As such, apical ES restructuring accompanied with the transit of developing spermatids during spermiogenesis must be segregated from the BTB to avoid an immunological barrier breakdown in all stages of the seminiferous epithelial cycle, except at stage VIII when spermiation and BTB restructuring take place concurrently. We report herein a mechanism involving restricted spatial and temporal expression of Arp2/3 complex and N-WASP, whose actin branching activity associated with apical ES and BTB restructuring in the seminiferous epithelium. High expression of Arp3 at the apical ES was shown to correlate with spermatid movement and proper spermatid orientation. Likewise, high Arp3 level at the BTB associated with its restructuring to accommodate the transit of preleptotene spermatocytes at stage VIII of the epithelial cycle. These findings were validated by in vitro and in vivo studies using wiskostatin, an inhibitor that blocks N-WASP from activating Arp2/3 complex to elicit actin branching. Inhibition of actin branching caused a failure of spermatid transit plus a loss of proper orientation in the epithelium, and a “tightened” Sertoli cell TJ permeability barrier, supporting the role of Arp2/3 complex in segregating the events of AJ and BTB restructuring. 相似文献
108.
Nicola E Wilsher Will J Court Ruth Ruddle Yvette M Newbatt Wynne Aherne Peter W Sheldrake Neil P Jones Matilda Katan Suzanne A Eccles Florence I Raynaud 《Drug metabolism and disposition》2007,35(7):1017-1022
Phosphoinositide-specific phospholipase C (PLC) is a key enzyme in the regulation of Ca(2+) release from inositol 1,4,5-triphosphate-sensitive stores. U73122 (1-(6-((17beta-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione) has been extensively used as a pharmacological inhibitor of PLC to elucidate the importance of this enzyme family in signal transduction pathways. U73122 has an electrophilic maleimide group, which readily reacts with nucleophiles such as thiols and amines. In the current study the conjugation of U73122 to common components of cell culture medium, namely l-glutamine, glutathione, and bovine serum albumin (BSA), was demonstrated. The half-life of U73122 on incubation with phosphate-buffered saline (PBS), Hanks' buffered saline solution (with 2 mM glutamine), optimized basal nutrient medium (MCDB131, without BSA), complete medium, Dulbecco's modified Eagle's medium (with 2 mM l-glutamine) was approximately 150, 60, 32, 30, and 18 min, respectively. However, U73122 was not recoverable from medium supplemented with 0.5% BSA. U73122 underwent hydrolysis of the maleimide group when incubated with PBS. Glutamine conjugates of U73122 were identified in cell culture medium. Furthermore, the inhibition of epidermal growth factor-stimulated Ca(2+) release in a human epidermoid carcinoma cell line (A431) by U73122 was substantially reduced by the presence of BSA in a time-dependent manner. In complex cellular assays, the availability of U73122 to inhibit PLC may be limited by its chemical reactivity and lead to the misinterpretation of results in pharmacological assays. 相似文献
109.
绝经后女性类风湿关节炎患者骨密度变化影响因素分析 总被引:2,自引:0,他引:2
目的探讨绝经后女性类风湿关节炎(RA)患者发生骨质疏松(OP)的原因。方法收集63例绝经后女性RA患者一般临床资料、疾病活动相关指标、手足X线资料,并同时测量患者7个部位的骨密度。结果23例患者(36.5%)有至少一处检测部位表现为低骨量。前臂和桡尺骨远端的低骨密度发生率(23.8%)与OP总发生率(28.6%)无显著性差异(P>0.05)。OP的发生与疾病活动指标及糖皮质激素的使用均无相关性。多元回归分析显示绝经的年限和关节腔狭窄为低骨量发生的独立危险因素(P<0.05);而雌激素替代疗法(HRT)为低骨量发生的唯一保护因素(P<0.05),小剂量糖皮质激素对本组患者的骨密度无影响。结论OP是绝经后女性RA患者的常见并发症,绝经年限长和关节破坏严重是低骨量发生的独立危险因素,HRT是防治低骨量的保护因素。 相似文献
110.